SCHEMBL3065369

SCHEMBL3065369

COc1cc(N)nc2ccccc12

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.62
HPGD P15428 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
NCF1 P14598 7/20 0.61
BACE1 P56817 2/20 0.59
ALOX15 P16050 1/20 0.58
KDM4E B2RXH2 2/20 0.55
ALDH1A1 P00352 2/20 0.55
MAPT P10636 1/20 0.55
HTT P42858 1/20 0.55
TLR8 Q9NR97 1/20 0.51
ADORA2A P29274 1/20 0.51
POLB P06746 2/20 0.50
NQO2 P16083 1/20 0.50
SLC2A1 P11166 1/20 0.50
RAD52 P43351 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11349234 0.81 NCF1 (0.56) LMNAHPGDSMN1; SMN2NCF1BACE1
SCHEMBL7805413 0.81 NCF1 (0.76) NCF1BACE1ALDH1A1TLR8
SCHEMBL23452956 0.80 NCF1 (0.90) NCF1BACE1
SCHEMBL266444 0.79 LMNA (0.64) LMNAHPGDSMN1; SMN2NCF1ALOX15
SCHEMBL28010962 0.79 LMNA (0.64) LMNAHPGDSMN1; SMN2ALOX15KDM4E
SCHEMBL30065410 0.79 HPGD (0.64) LMNAHPGDSMN1; SMN2ALOX15KDM4E
SCHEMBL29877118 0.79 LMNA (0.64) LMNAHPGDSMN1; SMN2NCF1ALOX15
SCHEMBL396614 0.79 HPGD (0.64) LMNAHPGDSMN1; SMN2ALOX15KDM4E
SCHEMBL11350348 0.79 ALDH1A1 (0.59) LMNAHPGDSMN1; SMN2NCF1KDM4E
SCHEMBL23412800 0.79 NCF1 (0.82) NCF1BACE1TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1359915-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM (US) 2004-07-21 EP claimed
EP-1359915-A1 UROTENSIN-II RECEPTOR ANTAGONISTS Smithkline Beecham (US) 2003-11-12 EP claimed
WO-2003013523-A1 SH3 PROTEIN DOMAINS AND THEIR LIGANDS ADELAIDE RESEARCH & INNOVATION PTY LTD (AU) 2003-02-20 WO claimed
WO-2002058702-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (GB) 2002-08-01 WO claimed
US-9932320-B2 Quinoline-based kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-04-03 US disclosed
US-9464076-B2 Benzothiophene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-10-11 US disclosed
US-9464076-B2 Benzothiophene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-10-11 US disclosed
US-9464076-B2 Benzothiophene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-10-11 US disclosed
US-20160024060-A1 BENZOTHIOPHENE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-01-28 US disclosed
US-20160024060-A1 BENZOTHIOPHENE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-01-28 US disclosed
US-20160024060-A1 BENZOTHIOPHENE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-01-28 US disclosed
EP-2975037-A1 BENZOTHIOPHENE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-01-20 EP disclosed
US-4279912-A ANTIALLERGENS, BRONCHODILATORS ROUSSEL UCLAF (FR) 1981-07-21 US disclosed
US-4247699-A REACTION OF AN ISATOIC ANHYDRIDE WITH MALONONITRILE FOLLOWED BY TREATMENT WITH A STRONG ACID OR BASE PFIZER INC. (US) 1981-01-27 US disclosed
US-4175193-A INTERMEDIATES FOR 1-OXO-1H-6-ALKOXYPYRIMDO(1,2-A)QUINOLINE-2-CARBOXYLIC ACID AND ESTER ANTIALLERGENS PFIZER INC. (US) 1979-11-20 US disclosed
US-4075343-A Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof PFIZER INC. (US) 1978-02-21 US disclosed
US-4066766-A 1-Oxo-6-substituted pyrimido [1,2-a]quinoline-2-carboxylic acids and derivatives thereof and their use as antiallergy agents PFIZER INC. (US) 1978-01-03 US disclosed
US-4031217-A PYRIMIDINE-QUINOLINE COMPOUNDS PFIZER INC. (US) 1977-06-21 US disclosed
US-4017625-A Anti-allergic N-(5-tetrazolyl)-1-oxo-1H-6-alkoxypyrimido-[1,2-a]quinoline-2-carboxamides and intermediates therefor PFIZER INC. (US) 1977-04-12 US disclosed
US-4014881-A ANTIULCER AGENTS PFIZER INC. (US) 1977-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024060-A1 BENZOTHIOPHENE DERIVATIVE PDE10A, PDE5A, PDE3B LMNA 3843/4885HPGD 1863/4885SMN1; SMN2 2785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.